Amarox Limited: UK Public Sector Contracts Won & Awards
SME·Companies House: Private Limited Company·Harrow·Nationwide (UK)·Main market: Pharmaceutical products
Companies House10997632 ↗
i
How many tenders this supplier has won.
Tenders with at least one award to it. Award records are shown too, because one framework can carry many call-offs.
i
How many different public bodies have awarded to this supplier.
Buyers named on its awards, with duplicate names merged.
i
How much this supplier has won, by published values.
Sum of award values where it was the only winner, VAT excluded, framework ceilings left out.
Not turnover. Not every award publishes a value.
i
Awards to this supplier in the last 12 months.
Award records dated in the last 12 months, against the two years before.
i
Contracts that finish in the next 18 months.
Contracts ending in that window by the published end date or, where only a duration is published, an estimate from signature plus duration (marked). Neither, not counted.
An end date does not confirm a new procurement.
i
In which regions this supplier wins work.
The region of each buyer it won from: the buyer’s office, placed by the official ONS postcode lookup. Each procedure counts once.
Where the buyer is based, not necessarily where the work was done; the tender page shows the published place of delivery.
Where they wini
In which categories this supplier wins.
Distinct awards by the main category of the lot, or of the procedure when no lot is named. Repeat publications count once.
An award counts once in each class it covers; classes can overlap.
i
In which categories this supplier wins.
Distinct awards by the main category of the lot, or of the procedure when no lot is named. Repeat publications count once.
An award counts once in each class it covers; classes can overlap.
55 awards (53 for a named lot, 96%, 2 for a whole procedure with no lot named) · top CPV classes, shares of all 55 awards. An award may cover more than one class.
3360 Pharmaceutical products54 awards · 98% · 52 awards naming a lot + 2 whole-procedure awards3369 Various medicinal products1 awards · 2% · awards naming a loti
How much this supplier has won, by published values.
Sum of award values where it was the only winner, VAT excluded, framework ceilings left out.
Not turnover. Not every award publishes a value.
Largest published awards iThe biggest published awards. Awards to a single supplier with a published value, largest first, so you can check the totals against the notice. A repeated framework total can appear here. Open the notice to check. | Authority | Awarded | Term | Published value |
|---|---|---|---|---|
| Proprietary Drugs | eTenderwales | — | — | £21,800 † |
Where their buyers arei
In which regions this supplier wins work.
The region of each buyer it won from: the buyer’s office, placed by the official ONS postcode lookup. Each procedure counts once.
Where the buyer is based, not necessarily where the work was done; the tender page shows the published place of delivery.
i
In which regions this supplier wins work.
The region of each buyer it won from: the buyer’s office, placed by the official ONS postcode lookup. Each procedure counts once.
Where the buyer is based, not necessarily where the work was done; the tender page shows the published place of delivery.
ITL1 region of the buyer office · known for 28 of 28 awarded procedures · each procedure counts once
Bidding recordi
Competitions this supplier is known to have bid in.
Lots on Procurement Act 2023 award notices naming it as a bidder, split into won and lost. The lot is the contest: three lots of a ten-lot notice is three wins and seven losses.
i
Competitions this supplier is known to have bid in.
Lots on Procurement Act 2023 award notices naming it as a bidder, split into won and lost. The lot is the contest: three lots of a ten-lot notice is three wins and seven losses.
Procurement Act 2023 award notices name every bidder · 2 notices name this supplier since 20 Aug 2025 · observed bids, not an estimate
i
Competitions this supplier is known to have bid in.
Lots on Procurement Act 2023 award notices naming it as a bidder, split into won and lost. The lot is the contest: three lots of a ten-lot notice is three wins and seven losses.
i
Frameworks and DPS this supplier got onto.
Lots appointed out of lots applied for. Kept apart from contract wins because almost every compliant bidder gets a place.
i
How many public bodies this supplier has bid to.
Buyers on notices that name it as a bidder, win or lose.
| Notice | Authority | Outcome | Bidders | Published |
|---|---|---|---|---|
| NHS National Framework for Transition products (Axitinib and Eltrombopag) | NHS England | not appointed | 15 | 4 Sept 2025 |
| NHS National Framework for Transition products (Nilotinib and Ticagrelor) | NHS England | not appointed | 17 | 20 Aug 2025 |
Bidder names come from Procurement Act 2023 award notices, which list every bidder (from 2025). Older notices name no bidders, so earlier contests do not appear here. Latest ten notices shown.
Who they sell toi
Which public bodies award work to this supplier.
Authorities named on its published awards, ranked by distinct procedures, duplicate names merged.
i
Which public bodies award work to this supplier.
Authorities named on its published awards, ranked by distinct procedures, duplicate names merged.
Authorities named on this supplier’s published awards · ranked by distinct procedures · a framework or DPS adds one award record per appointed supplier
i
What kinds of public bodies award work to this supplier.
Its award records by the authority’s published type, otherwise by its name. One framework can add many records.
NHS & health84%(46 awards)
46 of 55 awards are NHS & health (84%).Type not classified15%(8 awards)
8 of 55 awards are Type not classified (15%).Central government2%(1 awards)
1 of 55 awards are Central government (2%).
| Authority | Procedures | Share | Award records | Last activity |
|---|---|---|---|---|
| NHS England | 16 | 57.1% | 30 | 5 Jan 2026 |
| The NHS Commissioning Board (operating under the name of NHS England) | 5 | 17.9% | 13 | 30 Nov 2021 |
| The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) | 3 | 10.7% | 4 | 9 Apr 2026 |
| Regional Business Services Organisation Procurement and Logistics Service | 2 | 7.1% | 6 | 23 Jun 2026 |
| eTenderwales | 1 | 3.6% | 1 | 17 Jun 2025 |
| The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) | 1 | 3.6% | 1 | 17 Apr 2026 |
Share = of the 28 procedures with an award naming this supplier. Last activity = award date, or notice publication when no award date was published.
Contracts endingi
Contracts that finish in the next 18 months.
Contracts ending in that window by the published end date or, where only a duration is published, an estimate from signature plus duration (marked). Neither, not counted.
An end date does not confirm a new procurement.
i
Contracts that finish in the next 18 months.
Contracts ending in that window by the published end date or, where only a duration is published, an estimate from signature plus duration (marked). Neither, not counted.
An end date does not confirm a new procurement.
44 of 55 awards carry an end date, 13 estimated from the duration · not a retender forecast
| Contract | Ends | Published value |
|---|---|---|
| NHS Framework for the supply of Licensed Antiretroviral Therapy (ART) for the treatment of HIV (Lot 1) & provision of a service to supply over labelled PrEP and PEP packs (Lot 2) 1 November 2024 | 31 Oct 2026 | £1 |
| Wave 15a - Hospital Only Products (DNW & DLN regions) | 31 Jan 2027 | £1 |
| Wave 15b - Orals (plus non-parenteral) products | 31 Jan 2027 | £1 |
| Wave 15b - Hospital Only (Housekeeping) All regions | 31 Jan 2027 | £1 |
| NP49425 Generic and Biosimilar Transition Medicines | 28 Feb 2027 | £64,103,740 |
| Wave 14c - Orals (plus non-parenteral) Products (all regions) | 31 May 2027 | £1 |
| Wave 15a - Orals (plus non-parenteral) Products (all regions) | 31 May 2027 | £1 |
| Orals (plus non-parenteral) Products | 31 May 2027 | £1 |
| Medicinal Products - Direct to Trust | 2 Jun 2027 estimated | £210,000,000 |
| Gastrointestinal, Endocrine, Blood, and Multiple Sclerosis Medicines | 31 Jul 2027 | £3,594,493 |
Soonest 10 of 13.
Recent awards
Latest 30 of 55 award records naming this supplier
About this data
- Source. Official UK public procurement notices (Find a Tender), reused under the Open Government Licence v3.0. New notices arrive through the day; the figures are rebuilt nightly.
- One profile per supplier. Built from award and contract notices that name this supplier; different spellings and registration numbers of the same company are merged into this profile.
- Values are published values. The table mirrors what the notice published: framework ceilings and joint awards are labelled and never counted as this supplier's money, and † marks a value taken from the contract notice when the award published none. Only awards made to this supplier alone count towards its value, excluding VAT. It is not turnover.
- Regions on this page are where the work is delivered, not the supplier’s registered address.
- Contract end dates. Published on 31 of 55 awards, estimated from the published duration on 13 more (marked “estimated”); those feed “Contracts ending”.
- Every figure shows what it rests on. Not every notice publishes a bid count, a value or a delivery region, so each figure carries the number of records behind it, and one built on few records is marked as such. The on a figure explains it; the counting rules are in the methodology. Spotted something wrong? Tell us.